Semaglutide vs Tirzepatide: Two Approaches to GLP-1 Research
Semaglutide and tirzepatide are the two most actively researched incretin-based peptide compounds, each representing a distinct pharmacological strategy. Semaglutide is a selective GLP-1 receptor agonist; tirzepatide is the first dual GIP/GLP-1 receptor agonist. Both have generated extensive clinical trial data, and both are available from BeaCapra at research-grade purity with batch-specific COAs.
This comparison covers molecular structure, mechanism of action, published trial data, pharmacokinetic profiles, and practical research considerations to help researchers select the appropriate compound for their protocols.
Head-to-Head Comparison
| Parameter | Semaglutide | Tirzepatide |
|---|---|---|
| Receptor Target | GLP-1R (selective) | GIP-R + GLP-1R (dual) |
| Molecular Weight | 4,113.58 Da | 4,813.45 Da |
| Molecular Formula | C187H291N45O59 | C225H348N48O68 |
| Amino Acids | 31 | 39 |
| CAS Number | 910463-68-2 | 2023788-19-2 |
| Half-Life | ~168 hrs (7 days) | ~120 hrs (5 days) |
| Fatty Acid Chain | C18 diacid | C20 diacid |
| DPP-4 Resistance | Aib at position 8 | Aib at position 2 |
| Base Sequence | GLP-1(7-36) analog | GIP(1-42) analog |
| Bioavailability (SC) | ~89% | ~80% |
| Steady State | 4-5 weeks | ~4 weeks |
| Dosing Frequency | Once weekly | Once weekly |
| FDA Approval | 2017 (T2D), 2021 (obesity) | 2022 (T2D), 2023 (obesity) |
| Key Trial Programs | SUSTAIN, STEP, PIONEER, SELECT | SURPASS, SURMOUNT |
| BeaCapra Size | 3 mg | 5 mg |
| BeaCapra Price | $129.99 ($110.49 sub) | $149.99 ($127.49 sub) |
| BeaCapra Purity | ≥99% HPLC | ≥99% HPLC |
Mechanism of Action: Selective vs Dual Agonism
Semaglutide: Selective GLP-1R Agonism
Semaglutide activates the GLP-1 receptor exclusively. This triggers three primary downstream effects: (1) glucose-dependent insulin secretion via pancreatic β-cell cAMP/PKA signaling, (2) glucagon suppression from α-cells, and (3) central appetite regulation through hypothalamic GLP-1R activation in POMC/CART neurons (PMID: 32773571). Additionally, GLP-1R agonism delays gastric emptying through vagal pathways.
Tirzepatide: Dual GIP/GLP-1R Agonism
Tirzepatide activates both receptors simultaneously, with approximately 5-fold higher potency at GIP-R versus GLP-1R (PMID: 30307095). GIP-R activation adds distinct biology:
- Adipose tissue effects: GIP-R activation enhances insulin sensitivity in adipocytes and may improve lipid handling (PMID: 33882607)
- Central appetite effects: GIP-R in the hypothalamus activates complementary appetite suppression pathways distinct from GLP-1R (PMID: 34293336)
- Beta-cell effects: GIP-R and GLP-1R co-activation produces additive or synergistic insulinotropic responses
The hypothesis — supported by SURPASS-2 data — is that dual receptor engagement captures a larger fraction of incretin biology than either receptor alone.
Clinical Trial Data Comparison
SURPASS-2: The Direct Comparison
SURPASS-2 (PMID: 34170646) is the only head-to-head randomized controlled trial comparing tirzepatide and semaglutide. It enrolled 1,879 adults with type 2 diabetes and compared tirzepatide (5, 10, or 15 mg weekly) versus semaglutide 1 mg weekly over 40 weeks.
| Endpoint | Tirzepatide 5 mg | Tirzepatide 10 mg | Tirzepatide 15 mg | Semaglutide 1 mg |
|---|---|---|---|---|
| HbA1c change | -2.01% | -2.24% | -2.30% | -1.86% |
| Weight change (kg) | -7.6 | -9.3 | -11.2 | -5.7 |
| Weight change (%) | -7.8% | -9.6% | -11.6% | -5.9% |
| ≥5% weight loss | 67% | 79% | 83% | 58% |
| ≥10% weight loss | 35% | 48% | 57% | 23% |
| HbA1c <7% | 82% | 86% | 86% | 79% |
All three tirzepatide doses achieved statistical superiority over semaglutide 1 mg for the primary endpoint of HbA1c reduction. Weight loss differences were also statistically significant at the 10 mg and 15 mg doses.
Important caveat: SURPASS-2 compared tirzepatide at three dose levels versus semaglutide at only its 1 mg dose. The 2.4 mg dose of semaglutide (used in the STEP obesity trials) was not included in this comparison.
Obesity Trials: STEP vs SURMOUNT
| Trial | Compound | Max Dose | Mean Weight Loss | Duration | PMID |
|---|---|---|---|---|---|
| STEP 1 | Semaglutide | 2.4 mg | -14.9% | 68 weeks | 33567185 |
| SURMOUNT-1 | Tirzepatide | 15 mg | -20.9% | 72 weeks | 35658024 |
| STEP 2 | Semaglutide | 2.4 mg | -9.6% | 68 weeks | 34170647 |
| SURMOUNT-2 | Tirzepatide | 15 mg | -14.7% | 72 weeks | 37385275 |
Cross-trial comparisons must be interpreted cautiously due to differences in study populations, inclusion criteria, and trial duration. However, the magnitude of weight reduction in SURMOUNT-1 (20.9%) exceeded that in STEP 1 (14.9%), consistent with the hypothesis that dual agonism produces enhanced metabolic effects.
Practical Research Considerations
When Researchers Choose Semaglutide
- Studying selective GLP-1R agonism in isolation
- Protocols requiring a longer half-life (~168 vs ~120 hours)
- Research building on the extensive SUSTAIN/STEP/SELECT dataset
- Cardiovascular outcome research (SELECT data available; no equivalent for tirzepatide yet)
- Oral formulation research (PIONEER program data exists for oral semaglutide)
When Researchers Choose Tirzepatide
- Studying dual GIP/GLP-1R agonism and incretin synergy
- Research requiring maximal metabolic effect (SURMOUNT-1 data)
- GIP-R biology investigation
- Comparative studies against selective GLP-1R agonists
- Adipose tissue insulin sensitivity research
BeaCapra Availability
Both compounds are available from BeaCapra at 99%+ HPLC-verified purity with batch-specific Certificates of Analysis and the industry's only subscribe & save program (15% off every order).
| Semaglutide | Tirzepatide | |
|---|---|---|
| Size | 3 mg | 5 mg |
| One-Time Price | $129.99 | $149.99 |
| Subscribe Price | $110.49 | $127.49 |
| Purity | ≥99% HPLC | ≥99% HPLC |
View Semaglutide → View Tirzepatide →
Frequently Asked Questions
Is tirzepatide better than semaglutide?
"Better" depends on the research question. In SURPASS-2, tirzepatide demonstrated superior glycemic and weight outcomes versus semaglutide 1 mg. However, semaglutide has cardiovascular outcome data (SELECT) that tirzepatide does not yet have. The compounds target different receptor profiles and may be suited to different research applications.
What is the main difference between semaglutide and tirzepatide?
Semaglutide selectively targets the GLP-1 receptor. Tirzepatide targets both the GIP and GLP-1 receptors simultaneously. This dual mechanism represents a fundamentally different pharmacological approach to incretin-based research.
Which has a longer half-life?
Semaglutide (~168 hours / 7 days) has a longer half-life than tirzepatide (~120 hours / 5 days). Both support once-weekly research dosing protocols.
Can I get both on subscription from BeaCapra?
Yes. BeaCapra is the only peptide supplier offering subscribe & save on both semaglutide and tirzepatide. Save 15% on each with automated delivery every 30, 60, or 90 days.
Which has more published research data?
Semaglutide has a larger body of published data, including the SUSTAIN (10 trials), STEP (5+ trials), PIONEER (10 trials), and SELECT cardiovascular outcomes trial — over 30,000 cumulative subjects. Tirzepatide's SURPASS (8 trials) and SURMOUNT (4+ trials) programs encompass over 20,000 subjects but started later.
All BeaCapra products are sold for research use only. Not for human consumption.